Table 3 Concomitant medication at baseline in CVOTs referred to in the text
Concomitant medication @baseline | Antihyperglycaemic medication N (%) | CV treatment N (%) | |||||||
|---|---|---|---|---|---|---|---|---|---|
Insulin | Metformin | Sulphonyl-urea | Aspirin | Statins | Antiplatelet/anticoagulant | Beta-blocker | ACEI/ARB | Other anti-hypertensives | |
SAVOR-TIMI53 | 6757 (40.9) | 11,094 (67.4) | 6332 (38.5) | 12,390 (75.2) | 12,892 (78.3) | 13,386 (81.3) | 10,117 (61.4) | 12,935 (78.5) | 6730 (40.9) |
EXAMINE | 1605 (29.8) | 3562 (66.2) | 2503 (69.9) | 4881 (90.7) | 4866 (90.4) | 5232 (97.2) | 4411 (81.9) | 4411 (81.9) | 1197 (22.2) |
TECOS | 3408 (23.2) | 11,966 (81.6) | 6645 (45.3) | 11,518 (78.5) | 11,719 (79.9) | 3167 (21.7) | 9322 (63.5) | 11,555 (78.8) | 4961 (33.8) |
ELIXA | 2292 (37.8) | 3834 (63.2) | 1863 (30.7) | 5726 (94.4) | 5621 (92.6) | 480 (7.9) | 5119 (84.4) | 5151 (84.9) | 1327 (21.9) |
EMPA-REG OUTCOME | 2374 (34.0)a | 3933 (55.9)a | 1383 (19.6) | 5990 (85) | 5387 (77) | – | 4537 (64) | 5651 (80) | 2114 (30) |
LEADER | 4159 (45.0)a | 7136 (76.4) | 4721 (50) | 5874 (63) | 6729 (72) | 6322 (67.7) | 5173 (55.4) | 7731 (83) | 920 (9.85) |
SUSTAIN 6 | 1 913 (58.0) | 2414 (73.2) | 1410 (42.8) | 2108 (63.9) | 2399 (72.8) | 406 (12.3) | 1894 (57.4) | 2753 (83.5) | 258 (7.8) |
EXSCEL | 6836 (46.3) | 11,295 (76.6) | 5401 (36.6) | 9380 (63.6) | 10,845 (73.5) | 10,835 (73.5) | 8211 (55.7) | 11,788 (79.9) | |
DEVOTE | 6409 (83.9) | 4564 (59.8) | 2229 (29.2) | 4764 (62.4) | 5972 (78.2) | 1599 (20.9) | 4370 (57.2) | 6182 (80.9) | 2458 (32.2) |
CANVAS program | 5095 (50.2) | 7825 (77.2) | 4361 (43) | – | 7599 (74.9) | 7466 (73.6) | 5421 (53.5) | – | – |
ACE | – | – | – | 6131 (94) | 6066 (93) | 6384 (98) | 4301 (66) | 3839 (59) | – |